Holen Sie sich die Stockscreener-App
57.64
0.24%
-0.14
Handel nachbörslich:
57.70
0.06
+0.10%
Schlusskurs vom Vortag:
$57.78
Offen:
$57.75
24-Stunden-Volumen:
15.21M
Relative Volume:
0.94
Marktkapitalisierung:
$85.67B
Einnahmen:
$20.62B
Nettoeinkommen (Verlust:
$3.56B
KGV:
24.17
EPS:
2.3847
Netto-Cashflow:
$3.48B
1W Leistung:
+1.46%
1M Leistung:
-7.14%
6M Leistung:
-42.91%
1J Leistung:
-44.84%
1-Tages-Spanne:
$57.26
$58.13
1-Wochen-Bereich:
$55.33
$58.51
52-Wochen-Spanne:
$52.52
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth - Yahoo Finance
Boston Scientific Corp. stock (US10117L1017): Q1 beat and raised guidance keep medtech on investors - AD HOC NEWS
BofA Cuts PT on Boston Scientific Corporation (BSX) Over Worries for Medtech - Yahoo Finance
Boston Scientific Corp. stock (US10117L1017): Pipeline momentum and earnings keep medtech investor i - AD HOC NEWS
Boston Scientific (BSX) Invests $1.5B in MiRus for Significant E - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific’s SWOT analysis: stock navigates strategic expansion - Investing.com
Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report? - Yahoo Finance
Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media
Insider Buying: Cheryl Pegus Acquires Shares of Boston Scientifi - GuruFocus
Boston Scientific director Cheryl Pegus buys $99,987 in stock - Investing.com UK
Boston Scientific director Ludwig buys $202,914 in stock By Investing.com - Investing.com Australia
Boston Scientific director Ludwig buys $202,914 in stock - Investing.com
Director Cheryl Pegus buys Boston Scientific (BSX) shares in open-market trade - Stock Titan
Director Edward J. Ludwig buys 3,580 Boston Scientific (BSX) shares in open market - Stock Titan
Boston Scientific (NYSE: BSX) director adds 4,450 company shares - Stock Titan
Boston Scientific Corp (NYSE:BSX) GARP Growth at a Reasonable Price Meets Strong Fundamentals - ChartMill
Boston Scientific’s strategic investment in MiRus includes option to acquire TAVR system - Today's Medical Developments
Mengis Capital Management, Inc.'s Boston Scientific Corp(BSX) Holding History - GuruFocus
Subgroup analysis of the Champion-AF trial shows age not a factor - BioWorld News
Boston Scientific stock (US10117L1017): Q1 sales rise as Wall Street tracks procedure demand - AD HOC NEWS
Boston Scientific Corporation (BSX) Fell Due to Weak Results - Yahoo Finance
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target - Insider Monkey
ODDO BHF ASSET MANAGEMENT SAS's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific Corp. stock (US10117L1017): market eyes next catalysts after recent updates - AD HOC NEWS
OXFORD ASSET MANAGEMENT LLP's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific (BSX) Achieves Positive Results in CAD Treatme - GuruFocus
Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results - Benzinga
Boston Scientific reports Seismiq IVL data from Fracture study - BioWorld News
Boston Scientific’s coronary IVL catheter hits primary endpoints in trial - Yahoo Finance
Boston Scientific stock rating reiterated at Buy by TD Cowen - Investing.com
Piper Sandler reiterates Boston Scientific stock rating on device outlook - Investing.com
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy? - Yahoo Finance
Boston Scientific coronary device meets trial endpoints - Investing.com
Boston Scientific posts positive data for coronary IVL catheter - Yahoo Finance
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints - Morningstar
Boston Scientific invests $1.5bn for equity stake in MiRus - Yahoo Finance
Boston Scientific Corp (BSX) Stock Up 6.2% and Still Undervalued -- GF Score: 83/100 - GuruFocus
Boston Scientific stock (US10117L1017): New catalyst watch after recent company developments - AD HOC NEWS
Boston Scientific Pairs US$2b Buyback With MiRus TAVR Growth Bet - Yahoo Finance
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years - Benzinga
Joel Greenblatt's Boston Scientific Corp(BSX) Holding History - GuruFocus
Boston Scientific (BSX) Announces $2 Billion Accelerated Share R - GuruFocus
Boston Scientific Corp Stock (BSX) Closed Up by 5.88% on May 18: Facts Behind the Movement - TradingKey
Boston Scientific invests $1.5B in MiRus heart valve startup - Yahoo Finance
Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal - Benzinga
BSX Reiterated by Needham -- Price Target Maintained at $77.00 - GuruFocus
Boston Scientific Bets on Growth Through Strategic M&A Deals - Yahoo Finance
Boston Scientific (BSX) Invests $1.5B in MiRus for 34% Equity St - GuruFocus
Boston Scientific returns to heart-valve market with $1.5B investment in startup - The Business Journals
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):